

Name of Company	Ticker Symbol	Name of Article by Tech Guru	Date Published	Investor Relations firm	Disclosure in Article
Agenus	AGEN	<a href="#">Agenus: A 'Beloved' Micro Cap... With An Interesting Pathway</a>	2/5/14	<a href="#">ProActive Capital</a>	<b>Disclosure:</b> I have no positions in any stocks mentioned, but may initiate a long position in AGEN over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Actinium Pharmaceuticals	ATNM	<a href="#">Actinium: Cash In The Bank And Catalysts Ahead</a>	2/4/14	<a href="#">ProActive Capital</a>	<b>Disclosure:</b> I have no positions in any stocks mentioned, but may initiate a long position in ATNM over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
		<a href="#">Actinium: Scarcity Value After Bayer Takeout Of Closest Peer</a>	12/3/13		<b>Disclosure:</b> I have no positions in any stocks mentioned, but may initiate a long position in <a href="#">OTCQB:ATNM</a> over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
		<a href="#">Actinium: Risk Reward Attractive, Catalysts Upcoming In '14</a>	10/14/13		<b>Disclosure:</b> I have no positions in any stocks mentioned, but may initiate a long position in <a href="#">OTC:ATNM</a> over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Coronado Biosciences	CNDO	<a href="#">Coronado: Separating Fact From Fiction</a>	7/24/13	<a href="#">ProActive Capital</a>	<b>Disclosure:</b> I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Inovio Pharmaceuticals	INO	<a href="#">Inovio IL-33 Results Provide Further Validation Of Platform</a>	2/3/14	<a href="#">ProActive Capital</a>	<b>Disclosure:</b> I have no positions in any stocks mentioned, but may initiate a long position in INO over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
		<a href="#">Inovio: Pullback Post-Roche Still A Compelling Entry Point</a>	11/4/13		<b>Disclosure:</b> I have no positions in any stocks mentioned, but may initiate a long position in <a href="#">INO</a> over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
IntelliPharma Ceutics International	IPCI	<a href="#">Strong Demand For Resistance Technology Bodes Well For IntelliPharmaCeutics</a>	12/17/13	<a href="#">ProActive Capital</a>	<b>Disclosure:</b> I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
		<a href="#">IntelliPharmaCeutics Sell Off On Acura Data Overdone... Compelling Entry Point</a>	8/28/13		Disclosure unavailable

THERMOGEN ESIS	KOOL	<a href="#">Cesca Merger Imminent: Path To 2x+ Returns Appears Achievable</a>	2/10/14	<a href="#">ProActive Capital</a>	<b>Disclosure:</b> I have no positions in any stocks mentioned, but may initiate a long position in KOOL over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Mesoblast	MBLTY	<a href="#">Mesoblast: Prochymal Deal Controversy Creates Buying Opportunity</a>	10/15/13	<a href="#">ProActive Capital</a>	<b>Disclosure:</b> I have no positions in any stocks mentioned, but may initiate a long position in <a href="#">OTCPK:MBLTY</a> over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
NeoStem	NBS	<a href="#">NeoStem: Catalysts Upcoming, Financing In Rear View Mirror</a>  <a href="#">NeoStem: A Three-Pronged Catalyst Story</a>	10/28/13  8/21/13	<a href="#">ProActive Capital</a>  <a href="#">LifeSci Advisors</a>	<b>Disclosure:</b> I have no positions in any stocks mentioned, but may initiate a long position in <a href="#">NBS</a> over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.  <b>Disclosure:</b> I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Neurotrope	NTRP	<a href="#">Neurotrope: Intriguing Play On Alzheimer's</a>	11/22/13	<a href="#">ProActive Capital</a>	<b>Disclosure:</b> I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Prima BioMed	PBMD	<a href="#">Prima BioMed: Trading Slightly Above Cash Despite 80% Of Addressable Market Being Intact</a>  <a href="#">Prima BioMed: Catalysts On The Way</a>	12/2/13  8/1/13	<a href="#">ProActive Capital</a>	<b>Disclosure:</b> I have no positions in any stocks mentioned, but may initiate a long position in <a href="#">PBMD</a> over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.  Disclosure unavailable
Soligenix	SNGX	<a href="#">Soligenix: 2 Contract Wins Validate Lean Operating Model Thesis</a>  <a href="#">Soligenix: Kirk Seal Of Approval, And Government Contract Catalyst Imminent</a>	9/26/13  8/14/13	<a href="#">ProActive Capital</a>	<b>Disclosure:</b> I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.  Disclosure unavailable
Therapeutics MD	TXMD	<a href="#">TherapeuticsMD Still Attractive Despite Run Up ... HRT Market Wide Open</a>	10/21/13	<a href="#">ProActive Capital</a>	<b>Disclosure:</b> I have no positions in any stocks mentioned, but may initiate a long position in <a href="#">TXMD</a> over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Unilife	UNIS	<a href="#">Assessing The Secondary Overhang At Unilife</a>  <a href="#">Unilife: Parsing The Debate</a>  <a href="#">Sanofi Contract Validates Thesis</a>  <a href="#">Unilife's Orbimed Deal Removes Dilution Risk &amp; Validates Platform</a>	12/26/13  12/4/13  9/9/13  3/13/14	<a href="#">ProActive Capital</a>	<p><b>Disclosure:</b> I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.</p> <p><b>Disclosure:</b> I am long <a href="#">UNIS</a>. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.</p> <p><b>Disclosure:</b> I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.</p> <p><b>Disclosure:</b> I have no positions in any stocks mentioned, but may initiate a long position in UNIS over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.</p>
VolitionRX	VNRX	<a href="#">VolitionRx: Catalyst Pathway And Compelling Set Up Warrant A Closer Look</a>  <a href="#">VolitionRX: Play The Trade In March, And Hold For Data In April</a>	9/23/13  3/10/14	<a href="#">ProActive Capital</a>	<p><b>Disclosure:</b> I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.</p> <p><b>Disclosure:</b> I have no positions in any stocks mentioned, but may initiate a long position in VNRX over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.</p>
WaferGen	WGBS	<a href="#">WaferGen: A Small Cap Play On The Attractive Sequencing Market</a>	2/28/14	<a href="#">ProActive Capital</a>	<p><b>Disclosure:</b> I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.</p>
Ampio Pharmaceuticals	AMPE	<a href="#">Strong Phase III Ampion Data Released Wednesday: Setting The Stage For Ampio</a>	8/15/13	<a href="#">LifeSci Advisors</a>	<p><b>Disclosure:</b> I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.</p>

Equinix	EQIX	<a href="#">Equinix REIT Status Misunderstood - Sell-Off Overdone</a>	6/13/13		<b>Disclosure:</b> I am long <a href="#">EQIX</a> . I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
BioAmber	BIOA	<a href="#">BioAmber: BDO Deal Adds Another Growth Leg To Sarnia Story</a>	1/23/2014	<a href="#">LifeSci Advisors</a>	<b>Disclosure:</b> I have no positions in any stocks mentioned, but may initiate a long position in BIOA, over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
		<a href="#">BioAmber 3Q: Sarnia Still On Track And Supports Valuation</a>	11/19/13		<b>Disclosure:</b> I have no positions in any stocks mentioned, but may initiate a long position in <a href="#">BIOA</a> over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
		<a href="#">BioAmber: A Disruptive Green Tech Platform With Attractive Upside And Sizeable Cash Cushion</a>	10/18/13		Disclosure unavailable
DelMar Pharmaceuticals	DMPI	<a href="#">DelMar Pharmaceuticals To Present Updated Phase I GBM Data At ASCO</a>	5/30/13	<a href="#">LifeSci Advisors</a>	<b>Disclosure:</b> I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Rockwell Medical	RMTI	<a href="#">Rockwell Medical CRUISE Data Is Positive - Implications For The Next Move</a>	7/12/13	<a href="#">LifeSci Advisors</a>	Disclosure unavailable
		<a href="#">Rockwell Medical: Short Thesis Has Played Out... Time To Re-Examine</a>	6/24/13		Disclosure unavailable
Sorrento Therapeutics	SRNE	<a href="#">Sorrento Has Multiple Shots On Goal, Worth A Closer Look</a>	6/20/13	<a href="#">LifeSci Advisors</a>	Disclosure unavailable
Stemline Therapeutics	STML	<a href="#">Stemline: An Oncology Company, Not A Regenerative Cell Therapy Company</a>	7/26/13	<a href="#">LifeSci Advisors</a>	<b>Disclosure:</b> I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
		<a href="#">Stemline, Targeting Cancer Stem Cells, Presented Promising Cancer Data At ASCO</a>	6/4/13	<a href="#">ProActive Capital</a>	Disclosure unavailable
LabStyle Innovations	DRIO	<a href="#">LabStyle Innovations: Ready For Launch</a>	8/27/13		<b>Disclosure:</b> I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

LeapFrog	NEON	<a href="#">Neonode Lands LeapFrog's New LeapPad Ultra</a>	6/29/13		<b>Disclosure:</b> I am long <a href="#">NEON</a> . I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Neonode	NEON	<a href="#">Neonode: Clearing Up The Confusion Ahead Of Imminent New Product Ramps</a>	12/2/13		<b>Disclosure:</b> I am long <a href="#">NEON</a> . I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
		<a href="#">It's Official: Neonode Has Landed Both LG And Samsung As Licensees</a>	9/5/13		<b>Disclosure:</b> I am long <a href="#">NEON</a> . I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
		<a href="#">Neonode To Unlock Value Of Its Non-Core Patents; Spin-Off Likely Worth \$9+ Per Share</a>	9/4/13		<b>Disclosure:</b> I am long <a href="#">NEON</a> . I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
		<a href="#">Fidelity Quadruples Neonode Stake To 15%, Adjusting Price Target Upwards</a>	8/14/13		<b>Disclosure:</b> I am long <a href="#">NEON</a> . I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
		<a href="#">Neonode Lands LeapFrog's New LeapPad Ultra</a>	6/29/13		<b>Disclosure:</b> I am long <a href="#">NEON</a> . I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
		<a href="#">Neonode Seems To Be Making Serious Headway At Sony</a>	6/19/13		<b>Disclosure:</b> I am long <a href="#">NEON</a> . I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
		<a href="#">Neonode Demos Ten Fingers And Looks Poised To Disrupt The Windows 8 Sensor Party</a>	6/6/13		Disclosure unavailable
		<a href="#">Neonode Likely In Sony's Dazzling 13.3" Slate</a>	5/21/13		<b>Disclosure:</b> I am long <a href="#">NEON</a> . I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
		<a href="#">Is NEON In Bed With</a>	5/17/13		<b>Disclosure:</b> I am long <a href="#">NEON</a> . I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
		<a href="#">Is NEON In Bed With</a>	4/30/13		<b>Disclosure:</b> I am long <a href="#">NEON</a> . I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

		<a href="#">NVDA? Certainly Sounds Like It...</a>  <a href="#">Neonode Strikes Down Apple's 'Slide To Unlock' Patent For The Third Time</a>  <a href="#">Neonode Officially, Yet Subtly, Proclaims Windows 8 Compliance</a>  <a href="#">Neonode Announces 'Flush Bezel,' Likely Close To Solving Windows 8 Touch Cost Conundrum</a>	4/4/13  3/6/13		<p>not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.</p> <p><b>Disclosure:</b> I am long <a href="#">NEON</a>. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.</p> <p><b>Disclosure:</b> I am long <a href="#">NEON</a>. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.</p>
PerkinElmer	PKI	<a href="#">PerkinElmer's 1Q Whiff: Time To Buy Or Stay Away?</a>	4/26/13		<b>Disclosure:</b> I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
ParkerVision	PRKR	<a href="#">ParkerVision: An Intriguing Opportunity Ahead Of October</a>	4/8/13		<b>Disclosure:</b> I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.